NASDAQ:RAIN - Rain Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $17.00
  • Forecasted Upside: 121.35 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$7.68
▼ -0.1 (-1.29%)

This chart shows the closing price for RAIN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Rain Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for RAIN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for RAIN

Analyst Price Target is $17.00
▲ +121.35% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Rain Therapeutics in the last 3 months. The average price target is $17.00, with a high forecast of $22.00 and a low forecast of $12.00. The average price target represents a 121.35% upside from the last price of $7.68.

This chart shows the closing price for RAIN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 5 investment analysts is to buy stock in Rain Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/18/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/19/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/17/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/15/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/13/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/14/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/13/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/12/2022

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/23/2022JonestradingInitiated CoverageBuy$17.00Low
6/2/2022Roth CapitalInitiated CoverageBuy$16.00High
5/27/2022Piper SandlerLower Price Target$26.00 ➝ $12.00Low
3/31/2022OppenheimerInitiated CoverageOutperform$15.00High
1/3/2022GuggenheimLower Price Target$26.00 ➝ $20.00High
11/10/2021Piper SandlerBoost Price TargetOverweight$25.00 ➝ $26.00High
9/14/2021The Goldman Sachs GroupDowngradeHold$22.00Low
7/20/2021Piper SandlerReiterated RatingOverweight$25.00Low
5/18/2021CitigroupInitiated CoverageBuyHigh
5/18/2021GuggenheimInitiated CoverageBuy$26.00High
5/18/2021Piper SandlerInitiated CoverageOverweight$25.00High
5/18/2021The Goldman Sachs GroupInitiated CoverageBuy$56.00High
(Data available from 8/12/2017 forward)

News Sentiment Rating

0.17 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/13/2022
  • 3 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/12/2022
  • 2 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
3/14/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
4/13/2022
  • 1 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
5/13/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
6/12/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/12/2022
  • 1 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
8/11/2022

Current Sentiment

  • 1 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Rain Therapeutics logo
Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is milademetan, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing milademetan which is in Phase 3 clinical trial for liposarcoma, Phase II clinical trial for solid tumors, and Phase II clinical trial for intimal sarcoma, as well as RAD52 which is in preclinical trials for tumors, including breast, ovarian, pancreatic, prostate, and other cancers. Rain Therapeutics Inc. was incorporated in 2017 and is headquartered in Newark, California.
Read More

Today's Range

Now: $7.68
Low: $7.37
High: $8.19

50 Day Range

MA: $5.01
Low: $2.22
High: $7.82

52 Week Range

Now: $7.68
Low: $2.15
High: $18.78

Volume

52,806 shs

Average Volume

130,748 shs

Market Capitalization

$203.75 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Rain Therapeutics?

The following Wall Street sell-side analysts have issued stock ratings on Rain Therapeutics in the last twelve months: Guggenheim, Jonestrading, Oppenheimer Holdings Inc., Piper Sandler, Roth Capital, and The Goldman Sachs Group, Inc..
View the latest analyst ratings for RAIN.

What is the current price target for Rain Therapeutics?

6 Wall Street analysts have set twelve-month price targets for Rain Therapeutics in the last year. Their average twelve-month price target is $17.00, suggesting a possible upside of 121.4%. The Goldman Sachs Group, Inc. has the highest price target set, predicting RAIN will reach $22.00 in the next twelve months. Piper Sandler has the lowest price target set, forecasting a price of $12.00 for Rain Therapeutics in the next year.
View the latest price targets for RAIN.

What is the current consensus analyst rating for Rain Therapeutics?

Rain Therapeutics currently has 1 hold rating and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe RAIN will outperform the market and that investors should add to their positions of Rain Therapeutics.
View the latest ratings for RAIN.

What other companies compete with Rain Therapeutics?

How do I contact Rain Therapeutics' investor relations team?

The company's listed phone number is 510-953-5559 and its investor relations email address is [email protected] The official website for Rain Therapeutics is www.rainthera.com. Learn More about contacing Rain Therapeutics investor relations.